NARDIL

This brand name is authorized in United States. It is also authorized in Australia, Canada, Estonia, Netherlands, New Zealand.

Active ingredients

The drug NARDIL contains one active pharmaceutical ingredient (API):

1	Phenelzine UNII 2681D7P965 - PHENELZINE SULFATE
	Phenelzine is an irreversible non-selective inhibitor of monoamine oxidase. Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron. Phenelzine is used for the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa.
	Read more about Phenelzine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NARDIL Film coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AF03	Phenelzine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AF Monoamine oxidase inhibitors, non-selective
Discover more medicines within N06AF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2856H
CA	Health Products and Food Branch	00476552
EE	Ravimiamet	1711640
NL	Z-Index G-Standaard, PRK	51314
NZ	Medicines and Medical Devices Safety Authority	11157
US	FDA, National Drug Code	0071-0350